{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "Patient underwent left upper lobe resection for squamous cell carcinoma two years prior to presentation.",
        "clinical_data": {
          "procedures": [
            {
              "name": "Left upper lobe resection",
              "date": null,
              "location": null,
              "performed_by": null,
              "outcome": null
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "squamous cell carcinoma",
              "status": "historical",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Developed mediastinal lymph node metastasis, confirmed by surgical biopsy.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C77.1",
              "label": "Mediastinal lymph node metastasis",
              "status": "active"
            }
          ],
          "procedures": [
            {
              "name": "Biopsy",
              "location": "Mediastinal lymph node",
              "outcome": "Confirmed metastasis"
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Immunohistochemical analysis of the PD\u2010L1 expression using a murine 22C\u20103 antibody showed that the tumour proportion score was 85%.",
        "clinical_data": {
          "labs": [
            {
              "test": "PD-L1 expression",
              "value": "85%",
              "unit": "%",
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Pembrolizumab treatment (200\u2009mg every three weeks) was initiated.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1661229",
              "dosage": "200 mg",
              "frequency": "every three weeks",
              "modality": "IV",
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Fourteen months after pembrolizumab initiation: Serum amylase and lipase increased to grade 2 (CTCAE version 4.1). PET-CT showed a round, highly integrated lesion with rough, irregular edges at the pancreatic head. CT scan showed slightly swollen pancreatic parenchyma and mild pancreatic duct dilation. Pancreatic tumour markers were elevated: CA19-9 149.3 U/mL (normal 0-36.9 U/mL), SPan-1 44.7 U/mL (0-30 U/mL), and DUPAN-2 412 U/mL (0-150 U/mL).",
        "clinical_data": {
          "labs": [
            {
              "test": "Amylase measurement",
              "value": "grade 2",
              "unit": "CTCAE version 4.1",
              "flag": "abnormal",
              "timestamp": null
            },
            {
              "test": "Lipase measurement",
              "value": "grade 2",
              "unit": "CTCAE version 4.1",
              "flag": "abnormal",
              "timestamp": null
            },
            {
              "test": "CA 19-9 level",
              "value": "149.3",
              "unit": "U/mL",
              "flag": "abnormal",
              "reference_range": "0-36.9 U/mL",
              "timestamp": null
            },
            {
              "test": "SPan-1 level",
              "value": "44.7",
              "unit": "U/mL",
              "flag": "abnormal",
              "reference_range": "0-30 U/mL",
              "timestamp": null
            },
            {
              "test": "DUPAN-2 level",
              "value": "412",
              "unit": "U/mL",
              "flag": "abnormal",
              "reference_range": "0-150 U/mL",
              "timestamp": null
            }
          ],
          "imaging": [
            {
              "type": "Positron emission tomography and computed tomography",
              "body_part": "Pancreatic Head",
              "modality": "PET-CT",
              "finding": "round, highly integrated lesion with rough, irregular edges",
              "impression": null,
              "date": null
            },
            {
              "type": "Computed tomography",
              "body_part": "Pancreas",
              "modality": "CT",
              "finding": "slightly swollen pancreatic parenchyma and mild pancreatic duct dilation",
              "impression": null,
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Prednisolone 90 mg (1 mg/kg/day) was administered.",
        "clinical_data": {
          "medications": [
            {
              "drug": "Prednisolone",
              "dosage": "90 mg",
              "frequency": "daily",
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Fifteen days after prednisolone initiation: PET-CT showed decreased integration at the pancreatic head, with no mass-like lesion. CT showed normalization of the size of the whole pancreas. Pancreatic tumour markers gradually decreased.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0032463",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "imaging": [
            {
              "type": "C0031007",
              "body_part": "C0030305",
              "modality": "PET",
              "finding": "decreased integration at the pancreatic head, with no mass-like lesion",
              "impression": null,
              "date": null
            },
            {
              "type": "C0031007",
              "body_part": "C0030305",
              "modality": "CT",
              "finding": "normalization of the size of the whole pancreas",
              "impression": null,
              "date": null
            }
          ],
          "labs": [
            {
              "test": "Pancreatic tumour markers",
              "value": null,
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "Four months after prednisolone initiation: Pancreatic tumour marker levels became normal.",
        "clinical_data": {
          "medications": [
            {
              "drug": "Prednisolone",
              "start_date": null,
              "end_date": null
            }
          ],
          "labs": [
            {
              "test": "Pancreatic tumour marker levels",
              "value": "normal",
              "unit": null,
              "flag": "normal",
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 8,
        "content": "Pancreatic exocrine enzymes and radiographic findings normalized.",
        "clinical_data": {}
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Progression of squamous cell carcinoma.",
        "transition_event": {
          "trigger_type": "progression",
          "trigger_entities": [
            "C0024296"
          ],
          "change_type": "progression",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Characterization of PD-L1 expression in mediastinal lymph node metastasis.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [
            "C4025334"
          ],
          "change_type": "addition",
          "target_domain": "lab"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Initiation of pembrolizumab treatment based on PD-L1 expression.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C1661229"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Development of pancreatic abnormalities and elevated pancreatic enzymes and tumor markers during pembrolizumab treatment.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0003123",
            "C0022121"
          ],
          "change_type": "progression",
          "target_domain": "symptom"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Administration of prednisolone for pancreatic abnormalities.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0032463"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Improvement in pancreatic abnormalities following prednisolone treatment.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0032463"
          ],
          "change_type": "other",
          "target_domain": "imaging"
        }
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "Normalization of pancreatic tumour marker levels after prednisolone treatment.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [],
          "change_type": "resolution",
          "target_domain": "lab"
        }
      }
    },
    {
      "from": "N8",
      "to": "N9",
      "data": {
        "edge_id": "H_to_I",
        "branch_flag": true,
        "content": "Normalization of pancreatic exocrine enzymes and radiographic findings.",
        "transition_event": {
          "trigger_type": "resolution",
          "trigger_entities": [],
          "change_type": "resolution",
          "target_domain": "imaging"
        }
      }
    }
  ]
}